2018-06-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/675014Abstract: Since late 2010, new variants of porcine epidemic diarrhea virus (PEDV) have caused high morbidity and mortality outbreaks in neonatal piglets resulting in a dramatic impact on swine industry. A new generation of vaccine against PEDV is urgently needed. In the past year, we have orally inoculated the PEDVPT-P96 in 8 month-old gilts and demonstrated that the PEDVPT-P96-inoculated gilts exhibited no clinical symptom, a transient low level of viral shedding for one to two days, and were capable to induce PEDV specific systemic IgG, suggests that the PEDVPT-P96 potentially being a good attenuated vaccine candidate used in sow. Similar to human rotaviruses, development of vaccine strategies to induce mucosal immunity is the absolute necessity but a difficult task for PEDV. To develop vaccine strategies for inducing PEDV-specific mucosal immunity, we aim to rapidly develop a safe and effective subunit and inactive vaccines for PEDV since the development of a live attenuated is time-consuming and labor intense. To overcome the limited mucosal immunity induced by the parenteral route, we plan to express porcine chemokine CCL25, CCL27/CTACK, and CCL28 as an adjuvant for inducing PEDV-specific mucosal immunity against PEDV via the intramuscular immunization route. The approaches not only help us to rapidly develop effective and easy-to-use subunit vaccines against PEDV but also provide an animal model serving for evaluating efficacy of other potential mucosal adjuvants. Furthermore, the information could provide a clue for other enteric pathogen vaccine development.